The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy.
Open accessAbstract
33 patients with advanced malignant melanoma were studied after intravenous administration of 131I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatic deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included simultaneous administration of both an 131I-labeled Fab specific for p97, and an 125I-labeled Fab not specific for p97. Blood clearance of p97-specific Fab was significantly more rapid than for nonspecific Fab. Eight of these patients had biopsies of subcutaneous nodules at 48 and 72 h postinjection in order to assess whether localization of radioactivity was antigen specific. Antigen-specific localization was observed with average ratios of specific/nonspecific uptake of 3.7 (48 h) and 3.4 (72 h); uptake was strongly correlated with tumor p97 concentration (r = 0.81, P less than 0.01). Also, imaging studies of the bio-distribution of 131I-labeled anti-p97 Fab in patients selected for high p97 tumor concentration showed avid tumor uptake and more prolonged retention of labeled Fab in tumor than in normal tissues. Based on these studies, we estimated that total 131I doses of 500 mCi could be safely given to patients before dose-limiting toxicity would be observed. Accordingly, in seven selected patients, phase I radiotherapeutic trials were begun. For improved radiation safety, we developed automated methods to label Fab fragments with up to 200 mCi of 131I. So far, a total of 12 individual therapeutic doses, ranging from 34 to 197 mCi of 131I-labeled to 5 to 10 mg of Fab, have been administered with excellent tumor localization and without major target organ toxicity. Cumulative doses ranged from 132 to 529 mCi 131I. Side effects attributable to the radiation were mild, with a transient drop slightly greater than 50% in platelet and absolute neutrophil counts being observed in the two patients who received cumulative doses greater than 500 mCi. In the combined series of 47 diagnostic and 12 therapeutic studies, four acute reactions were observed: one episode each of transient chills and fever; flushing and hypotension; and two skin rashes. All of these reactions responded promptly to symptomatic therapy. After multiple administrations of 131I-(anti-p97) Fab (IgG1), isotype-specific immunity was observed in three patients. In two of these patients it was possible to successfully reinfuse after immunity had developed with 131I-(anti-p97) Fab of a different isotype (IgG2a). Dosimetry estimates were performed based on the biodistribution of (131)I-Fab in these patients,and for every 100 mCi of (131)I-Fab given, tumor receives 1,040 rads; liver. 325 rads; and bone marrow, 30 rads. Marrow would be expected to be the critical organ, if doses >500 mCi (131)I-Fab are given. These studies demonstrated that, with proper precautions, large doses (of an (131)I-labeled murine Fab fragments immunologically specific for a human melanoma-associated antigen) could be safely given to humans by using repetitive intravenous injections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldenberg, D. M., DeLand, F., Kim, E., Bennett, S., Primus, F. J., van Nagell, J. R., Estes, N., DeSimone, P., & Rayburn, P. (1978) · New England Journal of Medicine · doi:10.1056/nejm197806222982503 · Cited by 756
(1962) · PubMed · Cited by 467
Mach, J.-P., Carrel, S., Forni, M., Ritschard, J., Donath, A., & Alberto, P. (1980) · New England Journal of Medicine · doi:10.1056/nejm198007033030102 · Cited by 393
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms.
Woodbury, R. G., Brown, J. P., Yeh, M. Y., Hellström, I., & Hellström, K. E. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.4.2183 · Cited by 261
Self-citationQuantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.
Brown, J. P., Woodbury, R. G., Hart, C. E., Hellström, I., & Hellström, K. E. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.539 · Cited by 247
Self-citationStructural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.
Brown, J. P., Nishiyama, K., Hellström, I., & Hellström, K. E. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.2.539 · Cited by 203
Self-citationSuppression of Thyroid Radioiodine Uptake by Various Doses of Stable Iodide
Sternthal, E., Lipworth, L., Stanley, B. A., Abreau, C. M., Fang, S.-L., & Braverman, L. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011063031903 · Cited by 125
Imaging approach in radioimmunodetection.
DeLand, F. H., Kim, E. E., Simmons, G. H., & Goldenberg, D. M. (1980) · PubMed · Cited by 104
Specific in vivo localization of monoclonal antibodies directed against the Thy 1.1 antigen.
Houston, L. L., Nowinski, R. C., & Bernstein, I. D. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.837 · Cited by 85
International Committee for Standardization in Haematology
(1986) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.1986.tb00135.x · Cited by 63
Cited by
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
Press, O. W., Eary, J. F., Badger, C. C., Martin, P. J., Appelbaum, F. R., Levy, R., Miller, R., Brown, S., Nelp, W. B., & Krohn, K. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1027 · Cited by 274
Self-citationZukotynski, K., Jadvar, H., Capala, J., & Fahey, F. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s31804 · Cited by 51
Metadata
- Authors
- Larson, S. M., Carrasquillo, J. A., Krohn, K. A., Brown, J. P., McGuffin, R. W., Ferens, J. M., Graham, M. M., Hill, L. D., Beaumier, P. L., & Hellström, K. E.
- Venue
- Journal of Clinical Investigation
- Published
- 1983-12-01
- Volume
- 72
- Issue
- 6
- Pages
- 2101-2114
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2026993269
- Cited by
- 261
- References
- 11
- FWCI
- 25.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. https://app.cochat.ai/papers/10.1172/jci111175
- The paper
- Larson, S. M., Carrasquillo, J. A., Krohn, K. A., Brown, J. P., McGuffin, R. W., Ferens, J. M., Graham, M. M., Hill, L. D., Beaumier, P. L., & Hellström, K. E. (1983). Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci111175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.